K.FaragoN.FurdanS.KovacsB.LovasS.et al
For queries, complaints, or support, please contact [email protected]
Nicholas Jones in Atlanta, offers peptide therapy in a private, relaxed setting
Key findings include: Unprecedented HbA1c reductions ranging from 1.9% to 2.6% across different trials and populations SURPASS-1 (monotherapy): Up to 92% of participants achieved HbA1c less than 7%, with 52% reaching normoglycemia (HbA1c less than 5.7%) SURPASS-2 (versus semaglutide 1 mg): GLP2 demonstrated superior HbA1c and weight reduction at all doses compared to the leading GLP-1 receptor agonist SURPASS-3 (versus insulin degludec): Superior glycemic control when added to metformin with or without SGLT2 inhibitors SURPASS-4 (versus insulin glargine): Improved outcomes in patients with elevated cardiovascular risk Across all SURPASS trials, GLP2 showed consistent efficacy with low rates of clinically significant hypoglycemia (blood glucose less than 54 mg/dL)
Customized Wellness Plans We assess your overall health to determine how B12 injections fit into your larger energy, metabolism, or hormone goals
GLP-1 receptor agonists are no longer niche therapies